BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/12/2020 3:08:42 AM | Browse: 775 | Download: 1302
 |
Received |
|
2019-12-31 07:20 |
|
Peer-Review Started |
|
2019-12-31 07:32 |
|
To Make the First Decision |
|
2020-03-02 04:03 |
|
Return for Revision |
|
2020-03-03 00:09 |
|
Revised |
|
2020-03-05 03:54 |
|
Second Decision |
|
2020-04-08 13:58 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-04-09 00:22 |
|
Articles in Press |
|
2020-04-09 00:22 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-04-14 01:27 |
|
Typeset the Manuscript |
|
2020-05-11 01:07 |
|
Publish the Manuscript Online |
|
2020-05-12 03:08 |
| ISSN |
2150-5330 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Xiu-Li Chen, Jing-Wei Mao and Ying-De Wang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ying-De Wang, MD, Chief Physician, Professor, Department of Gastroenterology, the First Affiliated Hospital of Dalian Medical University, No. 222, Zhongshan Road, Xigang District, Dalian 116011, Liaoning Province, China. albertwyd@163.com |
| Key Words |
Inflammatory bowel disease; Ulcerative colitis; Crohn’s disease; Granulocyte and monocyte apheresis; Therapy; Efficacy |
| Core Tip |
Conventional therapies for inflammatory bowel disease (IBD) patients including mesalazine, corticosteroids, and immunosuppressants have been used for decades with unsatisfactory outcomes either due to their ineffectiveness or side effects. Although the emerging biologic agents including anti-TNF mono-antibodies have revolutionized IBD treatment, severe opportunistic infections, primary or secondary loss of response and etc. are the major clinical concerns of clinicians and patients as well. In recent years, selective granulocyte and monocyte apheresis, as a therapeutic option for IBD patients, have been used in Japan, Europe, China and elsewhere for its advantages of satisfactory efficacy, and particularly high safety profile. It is hopeful that granulocyte and monocyte apheresis therapy will become an important, and yet promising therapeutic option for patients with IBD. |
| Publish Date |
2020-05-12 03:08 |
| Citation |
Chen XL, Mao JW, Wang YD. Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future. World J Gastrointest Pathophysiol 2020; 11(3): 43-56 |
| URL |
https://www.wjgnet.com/2150-5330/full/v11/i3/43.htm |
| DOI |
https://dx.doi.org/10.4291/wjgp.v11.i3.43 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
